Plasma half-life raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-07 and is reviewed periodically as new material appears.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Those with numerous transport vesicles, which are found primarily in skeletal muscles, fingers, gonads, and skin. Those with few vesicles, which are primarily found in the central nervous system. These capillaries are a constituent of the blood–brain barrier.
=== Decoding by high throughput sequencing === According to the complexity of the DNA encoded chemical library (typically between 103 and 106 members), a conventional Sanger sequencing based decoding is unlikely to be usable in practice, due both to the high cost per base for the sequencing and to the tedious procedure involved. High throughput sequencing technologies exploited strategies that parallelize the sequencing process displacing the use of capillary electrophoresis and producing thousands or millions of sequences at once. In 2008 was described the first implementation of a high-throughput sequencing technique originally developed for genome sequencing (i.e. "454 technology") to the fast and efficient decoding of a DNA encoded chemical library comprising 4000 compounds. This study led to the identification of novel chemical compounds with submicromolar dissociation constants towards streptavidin and definitely shown the feasibility to construct, perform selections and decode DNA-encoded libraries containing millions of chemical compounds. Now decoding of DNA-encoded libraries using commercial next-generation DNA sequencing platforms (e.g. Illumina) is the standard approach.
It was not discovered to act as a very weak (3.5 orders of magnitude less potent) gabapentinoid until 2015. Baclofen marketed under the brandname of Lioresal was introduced in the United States in 1977 for the treatment of spasticity is chemically similar to phenibut but is usually not considered a gabapentinoid. Mirogabalin, under the brand name Tarlige, was approved for the treatment of neuropathic pain and postherpetic neuralgia in Japan in January 2019. Gabapentenoid consumption appears to be increasing; between 2008 and 2018, gabapentenoid use increased by over 17% averaged worldwide, led by growing consumption in the US, Canada, and northern Europe.
=== Economics === Pembrolizumab was priced at US$150,000 per year when it launched in 2014. It was added to the Cancer Drugs Fund list of NHS England in November 2022 after a deal with manufacturer Merck Sharp and Dohme, the details of which remain confidential. Keytruda was the world's top-selling drug in 2024, with $29.5 billion in sales.
== Mistakenly attributed NASA spin-offs == The following is a list of technologies sometimes mistakenly attributed directly to NASA. In many cases, NASA popularized technology or aided its development, due to its usefulness in space, which ultimately resulted in the technology's creation.
Sources: en.wikipedia.org
History of nutritional science – progress in general health- and lifespan-related nutritional science List of causes of death by rate – such as R&D on the reduction of environmental toxins Years of potential life lost (YPLL) and Loss of life expectancy (LLE) General medicine and preventive healthcare and interventions against any specific aging-related disease Progress in tools and knowledge that can be used for anti-aging purposes such as CRISPR gene editing General regeneration in humans, organ printing and xenotransplantation progress Research about sustained brain health in general Maintaining health – conventional ways of maintaining and protecting health for life extension Health effects of exercise Neurobiological effects of physical exercise Public health / health policy including environmental policy and consumer protection
== Production == Affibody molecules are based on a three-helix bundle domain, which can be expressed in soluble and proteolytically stable forms in various host cells on its own or via fusion with other protein partners. They tolerate modification and are independently folding when incorporated into fusion proteins. Head-to-tail fusions of Affibody molecules of the same specificity have proven to give avidity effects in target binding, and head-to-tail fusion of Affibody molecules of different specificities makes it possible to get bi- or multi-specific affinity proteins. Fusions with other proteins can also be created genetically or by spontaneous isopeptide bond formation. A site for site-specific conjugation is facilitated by introduction of a single cysteine at a desired position, therefore this engineered protein can be used to conjugate to radionuclides such as technetium-99m and indium-111 to visualize receptor-overexpressing tumors. A number of different Affibody molecules have been produced by chemical synthesis. Since they do not contain cysteines or disulfide bridges, they fold spontaneously and reversibly into the correct three-dimensional structures when the protection groups are removed after synthesis. In some studies, temperatures above the melting temperature have been used, with retained binding properties following return to ambient conditions. Cross-linked variants have been produced as well.
Others include amber/traditional green, red/pure green, red/blue, and blue/pure green. RGB tri-color Tri-color LEDs contain three different LED emitters in one case. Each emitter is connected to a separate lead so they can be controlled independently. A four-lead arrangement is typical with one common lead (anode or cathode) and an additional lead for each color. Others have only two leads (positive and negative) and have a built-in electronic controller. RGB LEDs consist of one red, one green, and one blue LED. By independently adjusting each of the three, RGB LEDs are capable of producing a wide color gamut. Unlike dedicated-color LEDs, these do not produce pure wavelengths. Modules may not be optimized for smooth color mixing. Decorative-multicolor Decorative-multicolor LEDs incorporate several emitters of different colors supplied by only two lead-out wires. Colors are switched internally by varying the supply voltage. Alphanumeric Alphanumeric LEDs are available in seven-segment, starburst, and dot-matrix format. Seven-segment displays handle all numbers and a limited set of letters. Starburst displays can display all letters. Dot-matrix displays typically use 5×7 pixels per character. Seven-segment LED displays were in widespread use in the 1970s and 1980s, but rising use of liquid-crystal displays, with their lower power needs and greater display flexibility, has reduced the popularity of numeric and alphanumeric LED displays. Digital RGB Digital RGB addressable LEDs contain their own "smart" control electronics.
Yuchanyan is an early Neolithic cave site in Dao County (Daoxian), Hunan, China. The site yielded sherds of ceramic vessels and other artifacts which were dated by analysis of charcoal and bone collagen, giving a date range of 17,500 to 18,300 years old for the pottery. The pottery specimens may be the oldest known examples of pottery. The cave yielded fragmentary remains of 2 or more ceramic vessels, in addition to large amounts of ash, a rich animal bone assemblage, cobble and flake artifacts, bone tools, and shell tools. The artifacts indicate that the cave was a Late Paleolithic foragers' camp. Here we report on the radiocarbon ages of the sediments based on analyses of charcoal and bone collagen. The best-preserved charcoal and bone samples were identified by prescreening in the field and laboratory. The dates range from around 21,000 to 13,800 cal BP. The age of the ancient pottery ranges between 18,300 and 15,430 cal BP. Charcoal and bone collagen samples located above and below one of the fragments produced dates of around 18,000. These ceramic potsherds therefore provide some of the earliest evidence for pottery making in China.
Sources: en.wikipedia.org
== Construction == The gene on a DNA sequence of interest can either be cloned from an existing sequence or developed synthetically. To clone a naturally occurring sequence in an organism, the organism's DNA is first cut with restriction enzymes, which recognize DNA sequences and cut them, around the target gene. The gene can then be amplified using polymerase chain reaction (PCR). Typically, this process includes using short sequences known as primers to initially hybridize to the target sequence; in addition, point mutations can be introduced in the primer sequences and then copied in each cycle in order to modify the target sequence. It is also possible to synthesize a target DNA strand for a DNA construct. Short strands of DNA known as oligonucleotides can be developed using column-based synthesis, in which bases are added one at a time to a strand of DNA attached to a solid phase. Each base has a protecting group to prevent linkage that is not removed until the next base is ready to be added, ensuring that they are linked in the correct sequence. Oligonucleotides can also be synthesized on a microarray, which allows for tens of thousands of sequences to be synthesized at once, in order to reduce cost. To synthesize a larger gene, oligonucleotides are developed with overlapping sequences on the ends and then joined together. The most common method is called polymerase cycling assembly (PCA): fragments hybridize at the overlapping regions and are extended, and larger fragments are created in each cycle.
Numerous analogues and derivatives of DMT are known. Some examples include tryptamine (T), N-methyltryptamine (NMT), serotonin (5-hydroxytryptamine; 5-HT), psilocin (4-HO-DMT), psilocybin (4-PO-DMT), 4-AcO-DMT (psilacetin), 4-PrO-DMT, bufotenin (5-HO-DMT or N,N-dimethylserotonin), and 5-MeO-DMT (mebufotenin; N,N,O-trimethylserotonin). Some further examples include methylethyltryptamine (MET), diethyltryptamine (DET), methylpropyltryptamine (MPT), dipropyltryptamine (DPT), methylisopropyltryptamine (MiPT), diisopropyltryptamine (DiPT), methylallyltryptamine (MALT), diallyltryptamine (DALT), and pyr-T (N,N-tetramethylenetryptamine) and their derivatives. Some lesser-known DMT derivatives include 1-methyl-DMT, lespedamine (1-MeO-DMT), 2-methyl-DMT, 4-methyl-DMT, 4-MeO-DMT, 4-fluoro-DMT, 5-methyl-DMT, 5-ethyl-DMT, 5-TFM-DMT, 5-EtO-DMT, 5-TFMO-DMT, 5-fluoro-DMT, 5-chloro-DMT, 5-bromo-DMT, 6-fluoro-DMT, 5,6-dibromo-DMT, 4,5-MDO-DMT, 4,5-DHP-DMT, 5,6-MDO-DMT, 5-MeS-DMT, 6-methyl-DMT, 6-HO-DMT, 6-MeO-DMT, 7-methyl-DMT, 7-MeO-DMT, NBoc-DMT (NB-DMT), α,N,N-TMT (α-Me-DMT), and α,N,N,O-TeMS (5-MeO-α-Me-DMT). Cyclized tryptamines containing DMT in their chemical structures include ibogalogs like ibogainalog and tabernanthalog; iboga alkaloids like ibogaine and noribogaine; lysergamides like ergine (LSA) and lysergic acid diethylamide (LSD); and partial ergolines and lysergamides like N-DEAOP-NMT, 10,11-seco-LSD, RU-28306 (4,α-methylene-DMT), RU-28251 (4,α-methylene-DPT), Bay R 1531 (LY-197206; 4,α-methylene-5-MeO-DPT), and NDTDI (8,10-seco-LSD), among others.
== Subsequent reverse vaccinology research == During the development of the MenB vaccine, scientists adopted the same Reverse Vaccinology methods for other bacterial pathogens. A Streptococcus and B Streptococcus vaccines were two of the first Reverse Vaccines created. Because those bacterial strains induce antibodies that react with human antigens, the vaccines for those bacteria needed to not contain homologies to proteins encoded in the human genome in order to not cause adverse reactions, thus establishing the need for genome-based Reverse Vaccinology. Later, Reverse Vaccinology was used to develop vaccines for antibiotic-resistant Staphylococcus aureus and Streptococcus pneumoniae
These included an 1870 plan for new armory for the 7th New York Militia, an 1880 plan for an opera house, another plan in 1881 for a New York Historical Society building, an 1893 plan for relocating the New York City Hall building, and a 1903 plan for a general post office.
Once a sequence has been isolated, it must be inserted into a vector. The easiest way to do this is to cut the vector DNA using restriction enzymes; if the same enzymes were used to isolate the target sequence, then the same "overhang" sequences will be created on each end allowing for hybridization. Once the target gene has hybridized to the vector DNA, they can be joined using a DNA ligase. An alternative strategy uses recombination between homologous sites on the target gene and the vector sequence, eliminating the need for restriction enzymes.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.